Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study

doi:10.1002/alz.12069

Published April 12, 2020 | Version v1

Journal article Open

Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study

1. Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
2. Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland ; Memory Clinic, University Hospital of Geneva, Geneva, Switzerland.
3. Department of Nuclear Medicine, Imaging Pole, Toulouse, University Hospital, Toulouse, France ; Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France.
4. Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden.
5. Department of Nuclear Medicine, University of Cologne, Cologne, Germany.
6. Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, Alzheimercenter, Amsterdam, the Netherlands.
7. Barcelona β Brain Research Center, Barcelona Spain, Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER‐BBN), Madrid Spain, Universitat Pompeu Fabra, Barcelona Spain
8. Janssen Pharmaceutica NV, Beerse, Belgium
9. Janssen Pharmaceutica RND, Titusville, New Jersey, USA.
10. Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
11. GE Healthcare, Life Sciences, Amersham, United Kingdom.
12. Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands ; Centre for Medical Image Computing, Medical Physics and Biomedical Engineering, UCL, London, United Kingdom.
13. Barcelona β Brain Research Center, Barcelona Spain, Universitat Pompeu Fabra, Barcelona Spain, Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid Spain

Abstract

Introduction: The Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) Prognostic and Natural History Study (PNHS) aims at understanding the role of amyloid imaging in the earliest stages of Alzheimer's disease (AD). AMYPAD PNHS adds (semi-)quantitative amyloid PET imaging to several European parent cohorts (PCs) to predict AD-related progression as well as address methodological challenges in amyloid PET.

Methods: AMYPAD PNHS is an open-label, prospective, multi-center, cohort study recruiting from multiple PCs. Around 2000 participants will undergo baseline amyloid positron emission tomography (PET), half of whom will be invited for a follow-up PET 12 at least 12 months later.

Results: Primary include several amyloid PET measurements (Centiloid, SUVr, BP_ND , R₁ ), and secondary are their changes from baseline, relationship to other amyloid markers (cerebrospinal fluid and visual assessment), and predictive value of AD-related decline.

Expected impact: Determining the role of amyloid PET for the understanding of this complex disease and potentially improving secondary prevention trials.

Notes

The project leading to this paper has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 115952. This Joint Undertaking receives the support from the European Union's Horizon 2020 research and innovation programme and EFPIA. FB is supported by the NIHR UCLH biomedical research center. This publication solely reflects the author's view and neither IMI nor the European Union, and EFPIA are responsible for any use that may be made of the information contained herein.

Files